Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05715515

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

Conditions: COVID-19, Influenza A, Influenza Type B

Sex: All
Phase: NA
Enrollment: 1531
Sponsor: Abbott Rapid Dx

Location: United States

Summary

This study is designed as an international prospective, multicentric, clinical study to investigate the performance and usability of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use and Self- Test devices for the qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in human nasopharyngeal (NP) and mid-turbinate nasal swabs, respectively.This study is part of the performance evaluation to support the CE conformity assessment procedures.

Eligibility Criteria

Inclusion Criteria:Subjects from all age groups, able and willing to provide written informed consent or assent, suspected of having a respiratory viral infection consistent with COVID-19 and/or Flu by their healthcare provider within the first five days of the onset of symptoms, and presenting at least two of the following symptoms: fever, headache, tiredness, dry cough, sore throat, runny or stuffy nose, muscle aches, loss of smell, loss of taste or shortness of breath, will be prospectively enrolled.Exclusion Criteria:Subject has had a nasal or a NP swab taken within the last 4 hours and is not available for further testing after 4 hours has elapsed.Subject has active nose bleeds or acute facial injuries/trauma.Subject has received a nasal vaccine (i.e., FluMist®) within the previous fourteen (14) days.Subject is currently taking or has taken an antiviral medication- e.g., Amantadine, Rimantadine, Relenza® (Zanamivir), Tamiflu® (Oseltamivir Phosphate), and Flumadine®-for influenza or COVID-19 within the previous thirty (30) days.Subject is currently enrolled in a study to evaluate an investigational drug.Self-tester or caregiver has prior medical or laboratory training.Self-tester or caregiver has a visual impairment that cannot be restored using glasses or contact lenses or lay user is unable to read the Instructions for Use.Subject has a condition deemed unfit to safely perform the test.Subject is unwilling or unable to provide informed consent.Vulnerable populations as deemed inappropriate for the study by the site's PI.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05715515). StuddyBuddy aggregates publicly available trial information.